Prelude Capital Management’s Arcus Biosciences RCUS Stock Holding History

Prelude Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,221	Closed	-$447K	–	1769
2020 Q4	$447K	Buy	+17,221	New	+$417K	0.01%	757
2020 Q3	–	Sell	-7,558	Closed	-$187K	–	2252
2020 Q2	$187K	Sell	7,558 -834	-10%	-$22.5K	0.01%	755
2020 Q1	$116K	Buy	+8,392	New	+$104K	0.01%	561
2019 Q3	–	Sell	-2,198	Closed	-$17K	–	1979
2019 Q2	$17K	Buy	+2,198	New	+$22K	﹤0.01%	1315
2018 Q3	–	Sell	-300	Closed	-$4K	–	1992
2018 Q2	$4K	Buy	+300	New	+$4.71K	﹤0.01%	1573

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Prelude Capital Management's RCUS Position: Q1 2021 in Review

Prelude Capital Management sold out of Arcus Biosciences (RCUS) in Q1 2021, closing a stake of 17,221 shares — an estimated $447K sold.

Prelude Capital Management first reported a position in RCUS in Q2 2018 and held it in 5 quarters. The position peaked at $447K in Q4 2020. 148 funds tracked by Wall St. Rank hold RCUS as of Q1 2021.

Prelude Capital Management reported no remaining Arcus Biosciences position as of Q1 2021 after selling out during the quarter.
Prelude Capital Management sold 17,221 Arcus Biosciences shares in Q1 2021, an estimated $447K.
Prelude Capital Management first reported a position in Arcus Biosciences in Q2 2018 and held it in 5 quarters.
Prelude Capital Management's Arcus Biosciences position peaked at $447K in Q4 2020.
148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.